viewMylan Inc.

Mylan surges after drawing line under EpiPen scandal

The share price reaction suggests the company may have got off lightly with a US$465mln settlement

EpiPen auto-injector
Branded or generic? That was the question

Mylan NV (NASDAQ:MYL) was a big riser in pre-market trade after the drugs giant revealed on Friday it had reached a settlement with the government.

The drugs maker has agreed to pay US$465mln in return for the US government dropping charges against it. The drugs firm had been accused of over-charging government agencies for its EpiPen Auto-Injector emergency allergy treatment.

From 2007, when Mylan acquired the product, it raised the price of life-saving EpiPen six-fold to more than US$600 for a packet of two, causing outrage among those who were dependent on the self-administered product.

Without admitting any wrong-doing, Mylan settled with the US Department of Justice.

“The question in the underlying matter was whether EpiPen Auto-Injector was properly classified with the Centers for Medicaid and Medicare Services (CMS) as a non-innovator drug under the applicable definition in the Medicaid Rebate statute and subject to the formula that is used to calculate rebates to Medicaid for such drugs,” Mylan’s statement said on Friday.

“EpiPen Auto-Injector has been classified with CMS as a non-innovator drug since before Mylan acquired the product in 2007 based on long-standing written guidance from the federal government," it noted.

News of the settlement coincided with Mylam lowering its earnings guidance for the year. The company now expects full year earnings per share to be somewhere in the range of US4.70 to US$4.90, versus previous guidance of US$4.85 to US$5.15.

The company attributed the downgrade largely to the previously announced changes in the EpiPen Auto-Injector Medicaid programs, and the upcoming launch of the (considerably cheaper) generic version of the injector.

Having drawn a line under an affair that reflected very badly on the company, Mylan’s shares shot up 11.5% to US$35.94, helped by broker Raymond James upgrading the stock to ‘strong buy’.

Quick facts: Mylan Inc.

Price: 14.53 USD

Market: NASDAQ
Market Cap: $7.52 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


GTI Resources upbeat as it kicks off aircore drilling program at Niagara...

Rob Holm, senior consultant with CSA Global, speaks with Proactive Australia's Andrew Scott following the news GTI Resources Ltd (ASX:GTR) has started an initial aircore drilling program at Niagara Gold Project near Kookynie in WA. CSA Global's managing the project and Holm says a 60-hole...

4 hours, 33 minutes ago

2 min read